Naoki Okumura,Noriko Koizumi,Morio Ueno,Yuji Sakamoto,Hiroaki Takahashi,Kana Hirata,Ryuzo Torii,Junji Hamuro,Shigeru Kinoshita,N. Okumura,N. Koizumi,M. Ueno,Y. Sakamoto,H. Takahashi,K. Hirata,R. Torii,J. Hamuro,S. Kinoshita

Abstract:AIM: To demonstrate the efficacy of Rho-associated kinase (ROCK) inhibitor Y-27632 for corneal endothelial wound healing both in in vitro and in vivo models.METHODS: As an in vitro model, cultivated cynomolgus monkey corneal endothelial cells were scraped to create a linear defect. The wound distance was then determined during a 24-h culture in the presence or absence of 10 μM of Y-27632. As an in vivo model, central corneal endothelium of Japanese white rabbits was damaged by transcorneal freezing, then 10 mM of Y-27632 was applied topically six times daily for 48 h. The wound area of the corneal endothelium was evaluated after 48 h.RESULTS: The mean wound distance in the cultured corneal endothelial cells was significantly shorter in the Y-27632 group than in the control group. In the rabbit model, the mean wound area of the Y-27632 group was significantly smaller than that of the control group.CONCLUSION: This study demonstrated that ROCK inhibitor Y-27632 promotes corneal endothelial wound healing both in in vitro and in vivo.

Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops